Imatinib Teva (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, blocking their activity. This inhibition stops downstream signaling pathways that promote cell division and survival, leading to reduced proliferation of malignant cells and, in many cases, induction of programmed cell death.

The dosage of Imatinib Teva is individualized by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional can determine the appropriate regimen.

Safety data for Imatinib Teva in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Imatinib Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and Ph+ ALL. Compared with newer agents, it has a well‑characterized safety profile and extensive clinical experience, though some newer inhibitors may offer activity against resistant mutations or different dosing schedules.

Imatinib Teva should be stored at temperatures below 25 °C in its original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Imatinib Teva is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events can include liver toxicity, severe neutropenia, cardiac failure, pulmonary hypertension, and rare hypersensitivity reactions. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should be reported to a healthcare provider promptly.

Imatinib Teva is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those taking medications that may cause dangerous drug interactions.